Search for Clinical Trial Results

Sponsored By

Meningococcal Infections - 25 Studies Found

Status Study
Completed Study Name: Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection
Condition: Meningococcal Infections
Date: 2007-03-21
Active, not recruiting Study Name: Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)
Condition: Meningococcal Infections
Date: 2015-09-30
Interventions: Biological: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals) All subjects will receive three doses of a T
Completed Study Name: Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Condition: Meningococcal Infection
Date: 2006-04-03
Interventions: Biological: Meningococcal C conjugate vaccine
Completed Study Name: Immunogenicity of the Booster Dose of Two MenC Vaccines
Condition: Meningococcal Infection
Date: 2006-10-25
Interventions: Biological: conjugated polysaccharide menC vaccine Booster vaccine dose at 14 to 18 months.
Completed Study Name: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Condition: Meningococcal Infections
Date: 2008-07-22
Interventions:
  • Biological: rMenB+OMV NZ
  • Biological: combi
Completed Study Name: Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
Condition: Meningococcal Infection
Date: 2011-04-14
Interventions:
  • Biological: Meningococcal vaccine GSK 134612

Completed Study Name: Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Date: 2008-02-20
Interventions:
  • Biological: MenACWY-CRM + MMRV

Completed Study Name: Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Condition: Meningococcal Infections
Date: 2008-01-31
Interventions:
  • Biological: MenACWY-CRM 1 inje
Completed Study Name: A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
Condition: MENINGOCOCCAL INFECTION
Date: 2015-08-20
Interventions:
  • Biological: Bivalent rLP2086 Vaccine

Recruiting Study Name: Duration of Immunity Study
Condition: Meningococcal Infection
Date: 2012-02-17
Interventions:
  • Procedure: blood sampling Bloo
Next >>>